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Abstract 
The sleep-wake cycle is a neurobiological phenomenon that shows intervals of 
activity alternating with restfulness that appears with a periodicity approximating 
the 24h day-night cycle. The sleep-wake cycle is under the control of diverse 
neuroanatomical and neurochemical systems, including monoaminergic, 
cholinergic, adenosinergic among many other systems. In addition, 
neuroanatomical 
centers linked to sleep promotion, such as hypothalamus, project to the cerebral 
cortex, subcortical relays and brainstem. In addition, the sleep-wake cycle has 
been associated to aberrant features known as sleep disorders. Here, we will 
discuss the role of specific gene expression on sleep disturbances. Given the 
expansion of the knowledge in the sleep-wake cycle area, it is indeed ambitious to 
describe all the genetics involved in the sleep modulation. However, in this chapter 
we reviewed the current understanding of the sleep disorders and gene 
expression. 
 
Keywords: CRISPR–Cas9; gene; insomnia; narcolepsy; restless legs syndrome; 
sleep-wake cycle. 
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Introduction 
Diverse neurobiological elements such as neurochemical, neuroanatomical, and 
genetic modulate the sleep-wake cycle. In addition, it has been described the link 
between gene expression and sleep disturbances. Among the most frequent, sleep 
alterations are insomnia and excessive daytime sleepiness. However, there are 
additional members of the sleep disturbance such as obstructive sleep apnea, 
narcolepsy, advanced sleep phase syndrome, restless legs syndrome, among 
others. Importantly, current evidence has demonstrated the genetic basis of 
multiple sleep disorders. Thus, it is likely that genetic phenomena contribute to the 
control of the sleep-wake cycle. Moreover, new therapeutical approaches aimed to 
manage sleep disorders should consider the genetics influence in the onset of 
pathologies related to sleep. 
 
1. The sleep-wake cycle: An Overview 
In humans, mammals and birds, three behavioral states can be readily 
distinguished: wakefulness (W), slow wave sleep (SWS) and rapid eye movement 
sleep (REMS).  Polysomnography is the basic tool used to differentiate these 
states (Figure 1).  It consists of the simultaneous recording of various physiological 
parameters such as the electroencephalogram (EEG), the electromyogram (EMG) 
and eye movements.  
 
PLEASE INSERT FIGURE 1 ABOVE HERE 
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Wakefulness 
During W, there is an optimal interaction with the environment that allows the 
development of various behaviors necessary for survival.  In humans, W is 
accompanied by awareness (consciousness) of the environment and internally 
generated stimuli such as hunger and thirst. The EEG recording of W is defined by 
the presence of high frequency (above 15 Hz) and low amplitude oscillations 
determined by the activity of thalamic and cortical neurons.  In spite of this, during 
relaxed W with the eyes closed, regular alpha (8-12 Hz) activity predominates in 
the occipital region.  
 
W-promoting neuronal networks, known as activating systems, are located in the 
reticular formation of the upper brainstem, postero-lateral hypothalamus and basal 
forebrain (1).   These neurons are critical for the generation and maintenance of W; 
lesion of these areas generates a deficit in the maintenance of W, including comma 
(2).  It is also important to note that Narcolepsy, a paradigmatic hypersomnia, 
occurs because of a degeneration of neurons of the postero-lateral region of the 
hypothalamus that synthesize and utilize the neuropeptides hypocretin 1 and 2 
(also called orexin A and B) as neuromodulators.  The hypocretinergic neurons 
promote W, and are part of the activating system (3, 4). Neurons that constitute the 
activating system inhibit SWS promoting neuronal networks (see below). In fact, 
waking and SWS promoting neuronal networks have reciprocal inhibition between 
them (1). 
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Slow wave sleep 
During sleep, there is a marked decrease in the interaction with the environment, 
an increase of the threshold for the reaction to external stimuli, and a decrease in 
somatomotor activity.  Furthermore, animals adopt a distinctive position to 
conserve heat. 
 
In healthy adults, the transition from W to sleep is into SWS sleep.  In humans, 
three SWS phases are distinguished according to the depth of the state: S1, S2 
and S3.  From W, normal adults enter in S1 or light SWS.  This transitional state 
present low-voltage, mixed frequency waves (2–7 Hz range) in the EEG.  The S2 is 
characterized by the presence of sleep spindles and K-complexes in the EEG.  
Sleep spindles are “spindle-like” bursts of oscillatory activity of 11-15 Hz with a 
duration of 0.5-2 seconds; the intervals between sleep spindles in human subjects 
are of 3 to 5 seconds (5).  These events are generated by the interplay of the 
reticular thalamic nucleus with others thalamic nuclei.  K-complex consists of a 
brief negative sharp high-voltage peak (usually greater than 100 µV), followed by a 
slower positive complex and final negative peak. K-complexes are often associated 
with sleep spindles. The S2 account for approximately 50% of the total sleep time 
during the night (6). The S3 is characterized by low frequency (0.5 to 4 Hz, delta 
band of frequencies) of high amplitude ( 75 V) waves in the EEG. S3 accounts 
for 12.5 to 20 % of the total sleep time (6). 
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Tonic parasympathetic activity increases during SWS determining characteristic 
changes in visceral activity, such as a pronounced decrease in heart rate (7). In the 
deeper stages of SWS, cognitive activity (i.e., dreams) is minimal (8-10). In the 
preoptic area of the hypothalamus are the main SWS promoting neuronal 
networks.  Most of these neurons are GABAergic and inhibits the activating 
systems in order to generate SWS (11). In fact, pioneer studies by Von Economo 
showed that lesions of this area generates a severe insomnia (12). 
 
REM sleep  
REMS occurs periodically, and in normal adults is always preceded by SWS.  
REMS is a deep sleep stage although the EEG is similar to that of W (high 
frequency and low amplitude oscillations); hence, it is also called "paradoxical" 
sleep.  REMS is also distinguished by fast, saccadic rapid eye movements and 
muscle atonia as evidenced in the EMG channel.  Muscle atonia is produced 
mainly by postsynaptic hyperpolarization of the spinal and brainstem motoneurons 
(13).  This REMS atonia is absent or reduced in REMS behavioral disorder, a 
parasomnia characterized by patients acting out their dreams (14).  Phasic 
changes in autonomic activity, that generates irregular visceral activity (such as 
increases and decreases in blood pressure), is also associated with REMS (15).  
This state is also characterized by a lack of homeostatic control of body 
temperature (16). 
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Cognitive activities not only occur during W. Dreams, which occur more 
prominently during REMS (8-10), are considered a special kind of cognitive activity 
or proto-consciousness (19).  REM sleep dreams are characterized by their 
vividness, single-mindedness, bizarreness and loss of voluntary control over the 
plot.  Attention is unstable and rigidly focused, facts and reality are not checked, 
violation of physical laws and bizarreness are passively accepted, contextual 
congruence is distorted and time is altered (18-20).  
 
Dreams and psychosis, share important characteristics such as internal 
perceptions independent of external stimulation with a general lack of criticism.  In 
addition, REMS shares neurophysiological, and neurochemical characteristics with 
psychosis; because of this fact, it is considered a natural model of this condition 
(21-23). 
REMS occupies 20–25% of total sleep in human adults, and appears about ~90 
minutes after sleep onset (REMS latency) (24).   A shortened REMS latency (the 
interval between the sleep onset and the appearance of the first REMS episode) is 
a biological marker of primary depression (25).  It is also considered to be a 
clinically significant pathological feature in narcolepsy (26).   
 
Sleep during the night shows four to five SWS-REMS cycles (the period from the 
sleep onset to the end of first REMS episode or the period from the end of a REMS 
episode to the subsequent REMS episode). The average length of human sleep 
cycles is about 90 to 110 minutes (27).   
 
9 
 
Neuronal networks of the ponto-mesencephalic reticular formation are necessary 
and sufficient for REMS generation (28).  These neuronal networks are also 
involved in the control of W (constitute the ascending reticular activating system).  
However, the activity of these neurons differs between W and REMS. More recent, 
neurons of the lateral hypothalamus and incerto-hypothalamic area that synthesize 
and employ the neuropeptide melanin-concentrating hormone (MCH) as 
neuromodulator, has been involved both in the generation of SWS and REMS (29, 
30).  In addition, malfunctioning of the MCHergic system may be involved in the 
pathophysiology of depression (31). MCH antagonists are considered promising 
antidepressive and anxiolytic drugs (32). 
 
Circadian and homeostatic regulation of sleep 
The physiological transition between W and sleep is regulated by a circadian and a 
homeostatic component (33).  Like all circadian rhythms, sleep and W are 
regulated by commands from the suprachiasmatic nucleus (SCN) of the 
hypothalamus.  The SCN receives photic information directly from the retina, and 
regulates the activity of both the hypnogenic and activating systems (34).  
Furthermore, through indirect modulation of the sympathetic system, the SCN 
regulates the release of melatonin from the pineal gland during the night (35).  
Melatonin has a weak sleep-promoting effect. 
 
The homeostatic component also regulates the sleep-wake cycle; i.e., prolonged W 
facilitates the generation of sleep.  Different lines of research have shown that 
sleep-promoting substances, including adenosine, are released and accumulated 
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during W (36, 37).  Adenosine promotes sleep by inhibiting the activating systems 
and stimulating SWS promoting systems.  Of interest, caffeine promotes W by 
blocking the receptors for adenosine (38). 
 
Sleep is also deeply modified with age.  In the newborn transition from W to sleep 
is often accomplishes through REMS (called active sleep in newborns).  The sleep 
cycle (alternation of SWS-REMS) period in newborn is of 50-60 minutes and the 
circadian organization is not present (39, 40).  In addition, a shortening in sleep 
duration, mainly related to the reduction in S3 and REMS, is associated with aging 
(27). 
  
2. Basis of Gene Expression 
It is widely accepted that genes are the database contained inside the nucleus of 
all cells, and are responsible of physical and functional characteristics of subjects. 
Since every gene contains a particular set of molecular instructions for codifying a 
specific protein, this process is known as gene expression (41, 42). Remarkably, 
there is a natural variation in human gene expression. Every single person 
possesses two copies of each gene (one comes from each parent) and in turn, 
each human being has its own genetic information, which was inherited from its 
progenitor. Thus, the physical characteristics, physiology and even predisposition 
to certain pathologic conditions are also coded in genes. However, it is worthy to 
mention that not all genes are active at all times. It seems that some genes 
respond only when they interact with the environment, remaining active only for a 
limited time window (43). Since some genes have been linked with sleep disorders, 
11 
 
this review provides a broad understanding of the present knowledge regarding the 
sleep disorders and genes expression. 
 
3. Gene Expression in pathological conditions 
As mentioned previously, genes contain molecular instructions for codifying a 
specific protein, including some aberrant features. Clinically, we can interpret this 
molecular event as pathology. Most known cases of diseases-linked to gene 
expression are cancer, diabetes, neurodegenerative disorders, obesity and many 
others (44). For example, in cancer, it has been reported that the protein named 
Semaphorin-3E (Sema3E) shows an overexpression in human pancreatic cancer. 
In addition, Sema3E has been suggested as a contributor to tumor progression 
and metastasis, since it has been detected in pancreatic cancer cells inducing 
cellular proliferation. In opposition, experimental Sema3E knockout animals, 
displays a suppression of cancer cellular proliferation and a reduction tumors’ size 
(45). Another example of the role of nuclear elements related to diseases is the 
mRNA. In this regard, osteoporosis is a common disease in aging population, and 
it has been suggested that this disturbance is related to the normal decalcification 
rate. The origin of this health problem has been associated to causes such as 
deficiency in vitamin D, calcium, addiction to alcohol, as well as gene expression. 
Recent evidence has demonstrated that circulating mRNAs levels in 
postmenopausal subjects could be used as potential biomarkers for osteoporosis 
(46). Given the complex relationship between health disturbances and gene 
expression, it is not a surprise the extensive of this field.  
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4. Sleep Disorders linked to Gene Expression 
Insomnia 
In previous chapters of the current book, several sleep disturbances have been 
described. Thus, we will avoid redundancy in information. In the case of insomnia, 
this sleep disturbance is characterized by the difficulty to initiate or maintain sleep. 
Regarding the genetic basis of insomnia, several pieces of evidence have reported 
the critical role of multiple circadian genes, such as CLOCK, PER, Timeless, etc., 
in subjects that present insomnia as well as mood disorders (47-53). Additional 
examples of relationship between specific gene expression and insomnia is the 
data reported about genes that are related to the duration of a precise state of 
vigilance. In this case, Per2 and Per3 activity have shown higher patters of 
expression and insomnia (51, 52).  
 
Additional genes have been added to the list of genes related to insomnia. For 
example, adenosine, GABA, serotonin transporter polymorphic region (5-HTTLPR), 
and orexin/hypocretin show higher pattern of expression in insomniac conditions 
(47). To further complicate the scenario, several reports have suggested the 
involvement of additional wake-related neurotransmitter systems, including 
dopaminergic system genes (i.e., dopamine transporter 1 (DAT1), catecholamine- 
O-methyltransferase (COMT), dopamine receptor D4 (DRD4) (47, 54)). Current 
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genome-wide association studies (GWAS) have reported novel genes that seems 
to be associated to insomnia, such as ABCC9 gene (rs11046209) (54-57). 
 
 
Obstructive Sleep Apnea 
The clinical feature of repeated cessation or attenuation of breathing (named 
“apneas” and “hypopneas”, respectively) during sleep is known as obstructive 
sleep apnea (OSA). This sleep disorder is also linked with several health 
dysfunctions such as hypertension, obesity, heart failure, among others (58). The 
first-line treatment given to subjects that present OSA comprises the use of an 
equipment that provides air pressure known as continuous positive airway 
pressure or CPAP (58, 59).  
 
The molecular mechanisms underlying OSA remain unclear. However, there is 
evidence that suggests the involvement of genes. In this regard, GWAS in 12,558 
Hispanic subjects found two novel loci at genome level with significance for apnea-
hypopnea index (60). In addition, it has been proposed that genes related with 
inflammation might be linked to OSA. Thus, inflammatory factors, including IL-6, IL-
8, and TNF-α, have been found highly expressed in patients with OSA (61, 62). 
Additional gene candidates for OSA promotion are the 5-hydroxytryptamine 
receptor 2A (5-HTR2A) and interleukin-6 (IL-6) (63, 64). 
 
Narcolepsy 
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The major symptoms of narcolepsy comprise excessive daytime sleepiness and 
cataplexy. Regarding the genetic basis of this sleep disorder, it has been 
suggested that the human leukocyte antigen (HLA)-DRB1 × 15:01-DQB1 × 06:02 
haplotype seems to be linked with narcolepsy (65-67). In addition, GWAS in 
525,196 single nucleotide polymorphisms (SNPs) have been identified outside of 
the HLA region and associated to narcolepsy (68). Recent studies have shown that 
SNP in the promoter region of chemokine (C-C motif) receptor 1 (CCR1) is also 
linked to narcolepsy.  
 
Advanced Sleep Phase Syndrome 
Earth's rotation once in about 24h with respect to the Sun, but once every 23h, 
56min, and 4s approximately with respect to the stars. Thus, this cycle named 
circadian rhythm has established a remarkable influence in neurobiological activity 
of several species, including humans. In this regard, the circadian rhythm has also 
evidenced the existence of pathological circadian-related issues, such as sleep 
disturbances (70-74). For example, the advance sleep phase syndrome is 
characterized by subjects complaint of early evening bedtimes or early morning 
awakenings. In this case, this abnormal feature of sleep onset is named advance 
sleep phase syndrome. This sleep disturbance is evident when social constraints 
force the patients to late bedtimes (75, 76).  
 
The sleep control under the influence of the circadian rhythm responds to specific 
genes. In this regard, approximately 10% of the population are homozygous for the 
5-repeat allele (PER3(5/5)) of a variable number tandem repeated polymorphism in 
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the clock gene named Per-3. Importantly, PER3(5/5) has been linked to morning 
preference, while homozygosity for the four-repeat allele (PER3(4/4)) seems to be 
associated with evening preference (77).  
 
Genetic studies have contributed to the understanding of the molecular basis of 
circadian rhythms and associated sleep disorders. In this regard, more than 20 
genes have been characterized, including PER 1, 2, and 3, the cryptochrome 
genes 1 and 2, and brain and muscle arnt-like protein-1 (Bmal1/Aryl hydrocarbon 
receptor nuclear translocator- like [ARNTL1], (78, 79)).  
 
It is worthy to mention that diurnal preference seems also to be the result of 
activation of specific genes. For example, diurnal preference and a polymorphism 
in Per-3 or polymorphism in aryl hydrocarbon receptor nuclear translocatorlike 2 
(ARNTL2) has been described (80). In addition, significant gene-associated loci 
with morningness has been suggested (81). Taking together, we can conclude that 
genes with circadian expression play a key role in modulation of sleep onset as 
well as in circadian-related sleep disturbances (82-86). 
 
Restless Legs Syndrome  
The restless legs syndrome is a pathological condition characterized by the urge to 
move the legs during W, and is associated with periodic leg movements during 
sleep.  
The substantia nigra, a critical brain area for modulating movement, is composed 
of dopaminergic neurons that project to the striatum; low iron concentration within 
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this area, seems to be involved in the genesis of this sleep disorder (87, 88). 
Although significant advances have been achieved in the understanding of the 
restless legs syndrome, the genetics of this sleep disorder are still unknown. 
Current evidence suggests that genes such as IL-ß or BTBD9 participate in the 
onset of the motor disorder (89, 90). In addition, since this sleep disturbance has 
familial aggregation, GWAS studies have identified single nucleotide 
polymorphisms linked to the restless legs syndrome, including SNP at loci MEIS1 
(91-93). Indeed, more research is needed to clarify the role of genes that are 
participating in the onset of the restless legs syndrome (87-94). 
 
5. Could we edit genes related to sleep disorders? The case of CRISPR-Cas9 
Recently, it has been reported the gene editing technique known as Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR). Briefly, CRISPR uses 
a guide RNA to send biological “scissors” -usually the CRISPR-associated protein, 
Cas9- to a precise spot to cut and make a substitution in the genome. As one can 
imagine, CRISPR-Cas9 provides the technology to manipulate genomic 
sequences, focusing in human diseases, such as HIV and cancer (95-99). 
Moreover, CRISPR-Cas9- might be also considered to editing genes in sleep 
disorders, such as insomnia, OSA, narcolepsy, advanced sleep phase syndrome, 
or restless legs syndrome (100, 101; Figure 2). Indeed, it is needed to explore of 
the use of CRISPR-Cas9 in animal models of sleep disorders before to consider it 
a "bench-to-bedside" approach (102, 103). 
 
PLEASE INSERT FIGURE 2 ABOVE HERE 
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Conclusions 
The sleep-wake cycle is a physiological phenomenon that displays, as many other 
functions, aberrant features that have been characterized as sleep disturbances. 
Within the family of sleep disorders, insomnia, OSA, narcolepsy, advanced sleep 
phase syndrome and restless legs syndrome, are some of the unhealthy features 
of sleep. Research aimed to understand the origin of sleep disturbances have 
included the studies of gene expression linked to those sleep pathologies. In this 
regard, identifying the genes related to sleep disturbances have made significant 
achievements in the sleep medicine area. Currently, the modern molecular 
technique CRISPR-Cas9 might be considered to editing genes and its putative use 
is highly tempting to regulate or eliminate the sleep disturbances. Indeed, further 
studies are required to describe the potential use of CRISPR-Cas9 in edition of 
genes related to sleep disorders. 
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Figure legends. 
Figure 1. Polysomnographic features of the sleep-wake cycle. The states of 
vigilance comprise: Wakefulness, slow wave sleep and rapid eye movement (REM) 
sleep by electroencephalogram (EEG) and electromyogram (EMG) traces. 
Wakefulness shows EEG patterns of rapid (alpha) activity (8-13Hz) and higher 
activity is recorded in the EMG. The slow wave sleep state displays EEG spindle 
activity as well as a low voltage, including K complexes and waves over 100μV of 
amplitude and less than 2Hz frequency accompanied with EMG reduced activity. 
REM sleep displays in the EEG, low voltage mixed frequencies (2-7Hz) as well as 
muscle twitches recorded in the EMG. Abbreviations: Electroencephalogram 
(EEG); electromyogram (EMG); rapid eye movement sleep (REMS). 
 
 
Figure 2. Putative model of Hypothetical use of CRISPR/Cas9 for editing genes 
related to sleep disorders. By molecular manipulation of genes linked to sleep 
disturbances, a novel therapeutical approach might represent an efficient treatment 
for insomnia, OSA, narcolepsy, advanced sleep phase syndrome, restless legs 
syndrome or other sleep disturbances.  
 
 
